Ionis Pharmaceuticals, Inc.
Modulation of factor 11 expression

Last updated:

Abstract:

Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.

Status:
Grant
Type:

Utility

Filling date:

29 Jul 2020

Issue date:

5 Jul 2022